AU2001264856A1 - Inhibitors of viral infection - Google Patents

Inhibitors of viral infection

Info

Publication number
AU2001264856A1
AU2001264856A1 AU2001264856A AU6485601A AU2001264856A1 AU 2001264856 A1 AU2001264856 A1 AU 2001264856A1 AU 2001264856 A AU2001264856 A AU 2001264856A AU 6485601 A AU6485601 A AU 6485601A AU 2001264856 A1 AU2001264856 A1 AU 2001264856A1
Authority
AU
Australia
Prior art keywords
inhibitors
viral infection
viral
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264856A
Other languages
English (en)
Inventor
Scott Hobson
Karla A. Kirkegaard
John M. Lyle
Kathy Richmond
Steve Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2001264856A1 publication Critical patent/AU2001264856A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001264856A 2000-05-24 2001-05-22 Inhibitors of viral infection Abandoned AU2001264856A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20688700P 2000-05-24 2000-05-24
US60206887 2000-05-24
PCT/US2001/016674 WO2001089560A1 (fr) 2000-05-24 2001-05-22 Inhibiteurs d'infection virale

Publications (1)

Publication Number Publication Date
AU2001264856A1 true AU2001264856A1 (en) 2001-12-03

Family

ID=22768399

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264856A Abandoned AU2001264856A1 (en) 2000-05-24 2001-05-22 Inhibitors of viral infection

Country Status (3)

Country Link
US (1) US20020164348A1 (fr)
AU (1) AU2001264856A1 (fr)
WO (1) WO2001089560A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536592A (ja) * 2001-05-31 2004-12-09 センター　ナショナル　デ　ラ　レシェルシェ　サイエンティフィック（シーエヌアールエス） フラビウイルスのキャッピング酵素と、このタンパク質の、抗ウイルス特性を持つ薬剤を試験する工程における利用
US20070112523A1 (en) * 2003-12-12 2007-05-17 Transtech Phama,Inc. Ligands for 17i as modulators of orthopox viruses and methods for discovery thereof
US9361427B2 (en) * 2011-02-01 2016-06-07 The Regents Of The University Of California Scar-less multi-part DNA assembly design automation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
WO1993001484A1 (fr) * 1991-07-11 1993-01-21 The Regents Of The University Of California Methode permettant d'identifier des sequences de proteines qui se plient pour former une structure en trois dimensions connue
US5884230A (en) * 1993-04-28 1999-03-16 Immunex Corporation Method and system for protein modeling
US6081766A (en) * 1993-05-21 2000-06-27 Axys Pharmaceuticals, Inc. Machine-learning approach to modeling biological activity for molecular design and to modeling other characteristics
US5434796A (en) * 1993-06-30 1995-07-18 Daylight Chemical Information Systems, Inc. Method and apparatus for designing molecules with desired properties by evolving successive populations
DE69925918T2 (de) * 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketosäure-derivate als hemmstoffe von polymerasen

Also Published As

Publication number Publication date
US20020164348A1 (en) 2002-11-07
WO2001089560A1 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
AU6111000A (en) Inhibitors of viral helcase
AU2001272258A1 (en) Viral polymerase inhibitors
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
AU2002256418A1 (en) Inhibitors of bace
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
AU2001294912A1 (en) Hydroxyesters of 7-desmethylrapamycin
AU2002363005A1 (en) Derivatives of uk-2a
AU2001258771A1 (en) -secretase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
AU1167602A (en) Methods of therapy for hiv infection
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
AU1408300A (en) Hiv infection inhibitors
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
AU2001268701A1 (en) Methods of enhancing adhesion
AU2001255090A1 (en) Cdk inhibitors having 3-hydroxychromen-4-one structure
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
AU2281601A (en) Treatment of viral infections using levovirinTM
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2001292947A1 (en) Methods for inhibition of viral infection
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
AU2002360673A1 (en) Gp41 inhibitor
AU5029801A (en) Copolymers of allylphosphonium salts
AU2001245414A1 (en) Treatment of allergies
AU2001264856A1 (en) Inhibitors of viral infection
AU2001251004A1 (en) Detection of viable agents